US 10,376,493 B2
Combined acetylcholinesterase inhibitor and quaternary ammonium antimuscarinic therapy to alter progression of cognitive diseases
Steven A. Rich, Canandaigua, NY (US)
Assigned to Qaam Pharmaceuticals, LLC, Canandaigua, NY (US)
Filed by Qaam Pharmaceuticals, LLC, Canandaigua, NY (US)
Filed on Aug. 10, 2016, as Appl. No. 15/233,188.
Application 14/513,631 is a division of application No. 13/778,530, filed on Feb. 27, 2013, granted, now 8,969,402, issued on Mar. 3, 2015.
Application 13/325,371 is a division of application No. 11/935,483, filed on Nov. 6, 2007, granted, now 8,097,633, issued on Jan. 17, 2012.
Application 15/233,188 is a continuation of application No. 14/513,631, filed on Oct. 14, 2014, granted, now 9,980,941.
Application 13/778,530 is a continuation in part of application No. 13/325,371, filed on Dec. 14, 2011, granted, now 9,084,753, issued on Jul. 21, 2015.
Application 14/513,631 is a continuation of application No. 13/778,556, filed on Feb. 27, 2013, granted, now 9,034,890, issued on May 19, 2015.
Claims priority of provisional application 60/865,893, filed on Nov. 15, 2006.
Prior Publication US 2016/0346248 A1, Dec. 1, 2016
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/40 (2006.01); A61K 31/325 (2006.01); A61K 31/27 (2006.01); A61K 31/137 (2006.01); A61K 31/216 (2006.01); C07D 207/12 (2006.01); C07D 451/00 (2006.01); A61K 31/445 (2006.01); A61K 31/435 (2006.01); A61K 31/4015 (2006.01); A61K 31/438 (2006.01); A61K 31/165 (2006.01); A61K 31/407 (2006.01); A61K 31/20 (2006.01); A61K 31/201 (2006.01); A61K 31/202 (2006.01); A61K 9/00 (2006.01); A61K 9/70 (2006.01); A61K 31/439 (2006.01)
CPC A61K 31/40 (2013.01) [A61K 9/0014 (2013.01); A61K 9/0053 (2013.01); A61K 9/7023 (2013.01); A61K 31/137 (2013.01); A61K 31/165 (2013.01); A61K 31/20 (2013.01); A61K 31/201 (2013.01); A61K 31/202 (2013.01); A61K 31/216 (2013.01); A61K 31/27 (2013.01); A61K 31/407 (2013.01); A61K 31/4015 (2013.01); A61K 31/435 (2013.01); A61K 31/438 (2013.01); A61K 31/439 (2013.01); A61K 31/445 (2013.01); C07D 207/12 (2013.01); C07D 451/00 (2013.01)] 10 Claims
 
1. A method for treating a neurodegenerative cognitive disorder, wherein the neurodegenerative disease cognitive disorder is selected from the group consisting of Alzheimer's Disease, Dementia with Lewy Bodies, Parkinson's Disease, Fronto-temporal dementia, and Progressive Supranuclear Palsy, comprising administering to a patient a therapeutic amount of glycopyrrolate and a therapeutic amount of rivastigmine.